bodrumsurf
Morgan Stanley has upgraded Sanofi (NASDAQ:SNY) to overweight from equalweight as a recent phase 3 data release for amlitelimab in atopic dermatitis (eczema) indicates it could be differentiated compared to Dupixent (dupilumab).
The investment bank upped its price target to $58